Stock Track | 3SBIO Soars 5.12% Intraday on Dual IND Approval for SSS67 and Pfizer Partnership

Stock Track

04/15

3SBIO's stock price surged 5.12% during intraday trading on Wednesday, marking a significant upward movement.

The rally appears driven by positive developments for the company's pipeline. Its independently developed drug candidate SSS67 has officially received Investigational New Drug (IND) approval from China's National Medical Products Administration (NMPA), following a prior IND clearance from the U.S. Food and Drug Administration (FDA). This represents a key dual-market regulatory milestone for the asset.

Further bolstering investor sentiment is the company's landmark partnership with Pfizer, a deal valued at up to over USD 6 billion, which includes a record-setting upfront payment of USD 1.4 billion for a domestically developed innovative drug. Analysts note that southbound capital flows, which were a key driver during the stock's previous major rally, remain a factor to watch.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1142533714"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1142533714\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1142533714?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-15 11:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1142533714","market":"hk","top_or_hot":-1,"title":"Stock Track | 3SBIO Soars 5.12% Intraday on Dual IND Approval for SSS67 and Pfizer Partnership","media":"Stock Track","content":"<p>3SBIO's stock price surged 5.12% during intraday trading on Wednesday, marking a significant upward movement.</p><p>The rally appears driven by positive developments for the company's pipeline. Its independently developed drug candidate SSS67 has officially received Investigational New Drug (IND) approval from China's National Medical Products Administration (NMPA), following a prior IND clearance from the U.S. Food and Drug Administration (FDA). This represents a key dual-market regulatory milestone for the asset.</p><p>Further bolstering investor sentiment is the company's landmark partnership with Pfizer, a deal valued at up to over USD 6 billion, which includes a record-setting upfront payment of USD 1.4 billion for a domestically developed innovative drug. Analysts note that southbound capital flows, which were a key driver during the stock's previous major rally, remain a factor to watch.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | 3SBIO Soars 5.12% Intraday on Dual IND Approval for SSS67 and Pfizer Partnership</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | 3SBIO Soars 5.12% Intraday on Dual IND Approval for SSS67 and Pfizer Partnership\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-04-15 11:51</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>3SBIO's stock price surged 5.12% during intraday trading on Wednesday, marking a significant upward movement.</p><p>The rally appears driven by positive developments for the company's pipeline. Its independently developed drug candidate SSS67 has officially received Investigational New Drug (IND) approval from China's National Medical Products Administration (NMPA), following a prior IND clearance from the U.S. Food and Drug Administration (FDA). This represents a key dual-market regulatory milestone for the asset.</p><p>Further bolstering investor sentiment is the company's landmark partnership with Pfizer, a deal valued at up to over USD 6 billion, which includes a record-setting upfront payment of USD 1.4 billion for a domestically developed innovative drug. Analysts note that southbound capital flows, which were a key driver during the stock's previous major rally, remain a factor to watch.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01530","symbol_name":"三生製藥","start_time":0,"source_url":"","article_id":"1142533714","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1142533714","pubTimestamp":1776225076,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"3SBIO's stock price surged 5.12% during intraday trading on Wednesday, marking a significant upward movement.The rally appears driven by positive developments for the company's pipeline. Its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01530":"三生制药"},"translate_title":"个股追踪|SSS67与辉瑞合作获双IND批准三生制药盘中大涨5.12%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01530":1},"content_text":"3SBIO's stock price surged 5.12% during intraday trading on Wednesday, marking a significant upward movement.The rally appears driven by positive developments for the company's pipeline. Its independently developed drug candidate SSS67 has officially received Investigational New Drug (IND) approval from China's National Medical Products Administration (NMPA), following a prior IND clearance from the U.S. Food and Drug Administration (FDA). This represents a key dual-market regulatory milestone for the asset.Further bolstering investor sentiment is the company's landmark partnership with Pfizer, a deal valued at up to over USD 6 billion, which includes a record-setting upfront payment of USD 1.4 billion for a domestically developed innovative drug. Analysts note that southbound capital flows, which were a key driver during the stock's previous major rally, remain a factor to watch.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}